C
CytomX Therapeutics Inc (CTMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$1.99
-0.06 (-2.70%)
Market Cap: $444.73M
Last updated: Nov 17, 2026 at 11:04 AM ET
CytomX Therapeutics Inc (CTMX) Valuation Multiples
CytomX Therapeutics (CTMX) trades at 31.0x sales and 1.5x book value. Its P/S of 31.0x is above its 5-year median of 1.8x. Its forward P/E is 14.2x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 14.2x |
| Price to sales | 31.0x |
| Price to book | 1.5x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 400.0% above 6.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 31.0x | 1.8x | 6.2x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 0.6x in 2024 to 26.5x in 2016.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $4.26 | N/A | 5.5x | 7.3x |
| 2024 | $1.03 | 2.6x | 0.6x | N/A |
| 2023 | $1.55 | N/A | 1.1x | N/A |
| 2022 | $1.60 | N/A | 2.0x | N/A |
| 2021 | $4.33 | N/A | 7.3x | N/A |
| 2020 | $6.55 | N/A | 4.4x | N/A |
| 2019 | $8.31 | N/A | 13.8x | 7.4x |
| 2018 | $15.10 | N/A | 10.4x | 5.2x |
| 2017 | $21.11 | N/A | 11.0x | 11.7x |
| 2016 | $10.99 | N/A | 26.5x | 5.1x |
Frequently Asked Questions About CTMX
What is CTMX's forward P/E ratio?
CytomX Therapeutics has a forward P/E ratio of 14.2x.
What is CTMX's price to sales ratio?
CytomX Therapeutics has a price to sales ratio of 31.0x.
CTMX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors